A clinical trial of INS1201 in patients with DMD
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs INS 1201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 16 Jan 2025 New trial record
- 10 Jan 2025 According to an Insmed media release, the company has received IND clearance for INS-1201 for treatment of patients with DMD form FDA. First patient dosing expected in the first half of 2025.